Clinical Medicine Insights. Oncology · 2026
Retrospective Analysis of the Clinical Efficacy, Safety, and Influencing Factors of Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatic Malignancies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Li, Sheng Yuling, Liang Xianxian, Yang Tao, Dong Li, Gao Dazhi, Chen Bo, Xu Tantan, Ai Min, Shan Husheng, Tang Jinjing, Zhang Longjiang, Shi Donghong, Zhu Xiaoli
Аннотация
BACKGROUND: Transarterial chemoembolization (TACE) is an established therapeutic modality for malignant hepatic tumors. This study assessed the clinical efficacy, adverse events, and factors associated with treatment outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of hepatic malignancies.
METHODS: Clinical data were collected from 94 patients with hepatic malignancies who underwent DEB-TACE. Treatment response was assessed in accordance with the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Postoperative complications and relevant hematological parameters were analyzed by reviewing clinical symptoms and laboratory/examination findings. Logistic regression analysis was used to identify factors associated with treatment outcomes.
RESULTS: Median follow-up duration was 29.0 months (range: 3.0-51.0 months). Treatment response assessment post-DEB-TACE revealed that 2 patients (2.1%) achieved a complete response (CR), 53 (56.4%) achieved a partial response (PR), 27 (28.7%) had stable disease (SD), and 12 (12.8%) developed progressive disease (PD). The overall objective response rate (ORR) was 58.5%, and the disease control rate (DCR) was 87.2%. Median progression-free survival (PFS) was 5.0 months (95% confidence interval [CI]: 3.7-6.3 months), and median overall survival (OS) was 15.0 months (95% CI: 7.6-22.4 months). Multivariate logistic regression analysis demonstrated that hematological parameters-including D-dimer levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels-were associated with patient prognosis and survival outcomes.
CONCLUSIONS: Drug-eluting bead transarterial chemoembolization is an effective treatment for various liver malignancies, associated with few manageable postoperative complications. In addition, d-dimer, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels may predict DEB-TACE efficacy.
METHODS: Clinical data were collected from 94 patients with hepatic malignancies who underwent DEB-TACE. Treatment response was assessed in accordance with the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Postoperative complications and relevant hematological parameters were analyzed by reviewing clinical symptoms and laboratory/examination findings. Logistic regression analysis was used to identify factors associated with treatment outcomes.
RESULTS: Median follow-up duration was 29.0 months (range: 3.0-51.0 months). Treatment response assessment post-DEB-TACE revealed that 2 patients (2.1%) achieved a complete response (CR), 53 (56.4%) achieved a partial response (PR), 27 (28.7%) had stable disease (SD), and 12 (12.8%) developed progressive disease (PD). The overall objective response rate (ORR) was 58.5%, and the disease control rate (DCR) was 87.2%. Median progression-free survival (PFS) was 5.0 months (95% confidence interval [CI]: 3.7-6.3 months), and median overall survival (OS) was 15.0 months (95% CI: 7.6-22.4 months). Multivariate logistic regression analysis demonstrated that hematological parameters-including D-dimer levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels-were associated with patient prognosis and survival outcomes.
CONCLUSIONS: Drug-eluting bead transarterial chemoembolization is an effective treatment for various liver malignancies, associated with few manageable postoperative complications. In addition, d-dimer, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels may predict DEB-TACE efficacy.